Junier抗原的最新研究进展

徐姿; 李树中; 李中华; 李凌波

doi:10.13201/j.issn.1004-2806-b.2019.04.024

Junier抗原的最新研究进展

- 1. 江苏大学附属昆山医院(江苏昆山, 215300);
- 2. 黑龙江省牡丹江市第二人民医院;
- 3. 长春博讯生物技术有限责任公司;
- △. 审校者

详细信息

通讯作者: 李树中,E-mail:kssyylsz@sina.cn

中图分类号: R457.1

收稿日期: 2018-12-20

Recent advances on erythrocyte blood group Junier antigen

More Information

Corresponding author: LI Shuzhong, E-mail: kssyylsz@sina.cn

Received Date: 20 December 2018

摘要

- Junier血型抗原 /
- 转运蛋白 /
- 膜分化抗原 /
- 乳腺癌耐药蛋白 /
- 输血性溶血
Abstract: Junier blood group antigens are high-frequency antigens in the past "series" of antigens.In 2012, the International Society for Blood Transfusion(ISBT) renamed the "system" antigen and named "JR";number:032.The gene locus of the antigen is Chromosome 4;4q22.1.The gene coding product is "ABCG2" transporter, composed of 655 amino acids, which is a glycoprotein that passes through the membrane of the erythrocyte 6 times.ABCG2 transporter is also known as "breast cancer resistance protein "(BCRP), which has the effect of "pumping" chemotherapeutic drugs out of the cell, preventing therapeutic drugs for breast cancer from reaching therapeutic targets at low concentrations in breast cancer cells.Junier antigen is also a membrane differentiation antigen and is CDw338, which involves in one of the red cell immune mechanisms.Junier antigen can cause transfusion hemolytic reaction and might be a clinically significant antigen.
- Junier blood group antigen /
- transporter /
- membrane differentiation antigen /
- breast cancer resistance protein /
- transfusion hemolysis

HTML全文

参考文献(18)

[1]	Mark K, Fung MD.AABB technical manual[M].18 Thedition:359-360.
[2]	Tiribelli M, Geromin A, Cavallin M.ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML[J].Eur J Haematol, 2017, 99:269-274.
[3]	Yu B, Gu D, Zhang X, et al.The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer[J].J Genet Genomics, 2017, 44:375-383.
[4]	Geoff Daniels.Human Blood Groups[M].3rd.2013:487-492.
[5]	Marion E, Reid.The Blood Group Antigen[J].FactsBook, 2012:635-639.
[6]	Pan L, Lin H, Tian S, et al.The sensitivity of glioma cells to pyropheophorbide-αmethyl ester-mediated photodynamic therapy is enhanced by inhibiting ABCG2[J].Lasers Surg Med, 2017, 49:719-726.
[7]	Wu HF, Hristeva N, Chang J, et al.Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions[J].J Pharm Sci, 2017, 106:2751-2757.
[8]	Son CN, Bang SY, Kim SH, et al.ABCG2 Polymorphism Is Associated with Hyperuricemia in a Study of a Community-Based Korean Cohort[J].J Korean Med Sci, 2017, 32:1451-1459.
[9]	Kim CK, Oh S, Kim SJ, et al.Correlation of IGF1R expression with ABCG2 and CD44 expressions in human osteosarcoma[J].Genes Genomics, 2018, 40:381-388.
[10]	Wieckhusen C, Rink G, Scharberg EA, et al.A new genetic background for the Jr(a-)blood group phenotype caused by theABCG2*439T allele encoding a p.Arg147Trp change[J].Transfusion, 2017, 57:3063-3064.
[11]	Stiburkova B, Pavelcova K, Zavada J, et al.Functional non-synonymous variants of ABCG2 and gout risk[J].Rheumatology(Oxford), 2017, 56:1982-1992.
[12]	Eclov RJ, Kim MJ, Chhibber A, et al.ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression[J].Pharmacogenet Genomics, 2017, 27:454-463.
[13]	Berardi P, Cote J, Vege S, et al.Two novel ABCG2 alleles resulting in a Jr(a-)phenotype[J].Transfusion, 2017, 57:2811-2812.
[14]	张志琴, 张黎雯, 谢怡萍, 等.Duffy血型系统抗原研究进展[J].临床血液学杂志, 2017, 30(4):327-330.
[15]	倪强, 李树中, 雒晶, 等.GIL抗原研究进展[J].临床血液学杂志, 2017, 30(10):812-814.
[16]	俞黎娅, 李树中, 雒晶晶.VEL血型抗原研究进展[J].临床血液学杂志, 2018, 31(2):161-163.
[17]	刘芸, 李树中, 李中华, 等.AUG血型抗原研究进展[J].临床血液学杂志, 2018, 31(6):485-490.
[18]	范春丽, 李树中, 李中华, 等.P1PK血型抗原研究进展[J].临床血液学杂志, 2018, 31(8):643-664.